ARS Pharmaceuticals, Inc.
SPRY
$8.54
$0.526.48%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -78.60% | -182.76% | -167.41% | -258.60% | -229.77% |
| Total Depreciation and Amortization | 41.79% | 1,337.93% | 1,761.90% | 1,450.00% | 2,445.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 100.36% | 79.66% | 170.99% | 315.06% | 149.66% |
| Change in Net Operating Assets | 182.54% | 30.11% | -137.22% | -127.99% | -565.79% |
| Cash from Operations | -10.32% | -203.53% | -225.20% | -443.92% | -507.18% |
| Capital Expenditure | -- | 100.00% | -40.71% | -34.21% | -9.64% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -4.68% | 123.77% | -364.09% | 485.64% | 445.85% |
| Cash from Investing | -4.38% | 123.70% | -367.46% | 484.08% | 441.41% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -91.45% | 16.11% | -29.56% | 394.86% | 181.01% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -98.78% | -- | -- | -- |
| Cash from Financing | -78.07% | -98.41% | 14,612.50% | 394.86% | 181.01% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -55.17% | -263.44% | 164.50% | 160.25% | 26.81% |